- Home
- INVE vs ANL Comparison
INVE vs ANL Comparison
Compare INVE & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- ANL
- Stock Information
- Founded
- INVE 1990
- ANL 2004
- Country
- INVE United States
- ANL Cayman Islands
- Employees
- INVE N/A
- ANL N/A
- Industry
- INVE Computer peripheral equipment
- ANL
- Sector
- INVE Technology
- ANL
- Exchange
- INVE Nasdaq
- ANL Nasdaq
- Market Cap
- INVE 82.2M
- ANL 79.0M
- IPO Year
- INVE 1997
- ANL 2023
- Fundamental
- Price
- INVE $3.44
- ANL $2.25
- Analyst Decision
- INVE Strong Buy
- ANL Strong Buy
- Analyst Count
- INVE 2
- ANL 2
- Target Price
- INVE $7.25
- ANL $9.00
- AVG Volume (30 Days)
- INVE 31.8K
- ANL 5.8K
- Earning Date
- INVE 03-05-2025
- ANL 03-04-2025
- Dividend Yield
- INVE N/A
- ANL N/A
- EPS Growth
- INVE N/A
- ANL N/A
- EPS
- INVE 3.10
- ANL N/A
- Revenue
- INVE $104,217,000.00
- ANL $5,000,000.00
- Revenue This Year
- INVE N/A
- ANL N/A
- Revenue Next Year
- INVE N/A
- ANL N/A
- P/E Ratio
- INVE $1.13
- ANL N/A
- Revenue Growth
- INVE 70.57
- ANL N/A
- 52 Week Low
- INVE $2.95
- ANL $1.85
- 52 Week High
- INVE $9.24
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- INVE 40.36
- ANL 57.33
- Support Level
- INVE $3.41
- ANL $2.00
- Resistance Level
- INVE $3.67
- ANL $2.15
- Average True Range (ATR)
- INVE 0.19
- ANL 0.11
- MACD
- INVE 0.01
- ANL 0.03
- Stochastic Oscillator
- INVE 12.20
- ANL 59.52
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.